Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Johan Abram Saliba"'
Autor:
Julie K. Fierle, Johan Abram-Saliba, Vasileios Atsaves, Matteo Brioschi, Mariastella de Tiani, Patrick Reichenbach, Melita Irving, George Coukos, Steven M. Dunn
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-14 (2022)
Abstract Anti-tumor therapies that seek to exploit and redirect the cytotoxic killing and effector potential of autologous or syngeneic T cells have shown extraordinary promise and efficacy in certain clinical settings. Such cells, when engineered to
Externí odkaz:
https://doaj.org/article/5272d46530e645cbb33e011fe7c50336
Autor:
Laureline Wetterwald, George Coukos, Vasileios Atsaves, Tatiana V. Petrova, Mariastella de Tiani, Julie K. Fierle, Steven M. Dunn, Johan Abram-Saliba, Matteo Brioschi
Publikováno v:
Cell Reports Medicine
Cell reports. Medicine, vol. 2, no. 8, pp. 100362
Cell reports. Medicine, vol. 2, no. 8, pp. 100362
Summary Tumor endothelial marker 1 (TEM1) is an emerging cancer target with a unique dual expression profile. First, TEM1 is expressed in the stroma and neo-vasculature of many human carcinomas but is largely absent from healthy adult tissues. Second
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b24f69fcb68372e7c2bc71062f003842
https://doi.org/10.1016/j.xcrm.2021.100362
https://doi.org/10.1016/j.xcrm.2021.100362
Autor:
Johan Abram-Saliba, George Coukos, Mariastella deTiani, Julie K. Fierle, Steven M. Dunn, Matteo Brioschi
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-15 (2019)
Scientific reports, vol. 9, no. 1, pp. 12815
Scientific Reports
Scientific reports, vol. 9, no. 1, pp. 12815
Scientific Reports
An early bottleneck in the rapid isolation of new antibody fragment binders using in vitro library approaches is the inertia encountered in acquiring and preparing soluble antigen fragments. In this report, we describe a simple, yet powerful strategy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a9faa601dc51e97e4b90c0d4fb49914
https://doi.org/10.1038/s41598-019-49233-7
https://doi.org/10.1038/s41598-019-49233-7
Autor:
Douglas Phillips, Christof Zitt, Thomas Göttler, Savira Ekawardhani, Ignacio Dolado, Gabriel Sigrist, Michael T. Stumpp, Karl G. Proba, Ulrike Fiedler, H. Kaspar Binz, Talitha Bakker, Andreas Cornelius, Johan Abram Saliba, Gaby Tresch
Publikováno v:
mAbs. 9(8)
MP0250 is a multi-domain drug candidate currently being tested in clinical trials for the treatment of cancer. It comprises one anti-vascular endothelial growth factor-A (VEGF-A), one anti-hepatocyte growth factor (HGF), and two anti-human serum albu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14630bc2592e16f419a4a0925dfa413f
https://pubmed.ncbi.nlm.nih.gov/29035637
https://pubmed.ncbi.nlm.nih.gov/29035637
Autor:
Johan Abram Saliba, Denis Villemagne, Caroline A. C. Hyde, Alexandra Giese, Kurt Ballmer-Hofer, Thomas Schleier, H. Kaspar Binz, Edward Stuttfeld
Publikováno v:
Molecular and cellular biology
Vascular endothelial growth factors (VEGFs) activate three receptor tyrosine kinases, VEGFR-1, -2, and -3, which regulate angiogenic and lymphangiogenic signaling. VEGFR-2 is the most prominent receptor in angiogenic signaling by VEGF ligands. The ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7fe4121f33f72904d91bd26e1b214b7